Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Chronic Obstructive Pulmonary Disease (COPD) is a serious, progressive lung disease that limits airflow in the lungs. It causes twice as many deaths than diabetes. COPD is preventable and treatable but not curable and by 2030 it is predicted to be the third leading cause of death worldwide. An important goal in the management of COPD is increasing a patient’s ability to live their life to the extent they love to and keep active for longer. Regardless of the severity of a patient’s disease, reducing the risk of exacerbations and therefore a worsening of the condition is crucial.